HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Trump, FDA plan to expedite psychedelic development

Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedite their research and development as remedies for severe mental health conditions, a seminal moment for a field long shunned ...

By Endpoints News · Apr 20, 2026 · via Endpoints News
Trump, FDA plan to expedite psychedelic development

Image: Endpoints News

Tags
policyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
STAT+: Insurers refuse to join Medicare pilot offering weight loss drugs to seniors at steep discount
PolicySTAT News ↗
STAT+: Insurers refuse to join Medicare pilot offering weight loss drugs to seniors at steep discount
Health insurers would have likely faced a financial strain by participating in the Medicare pilot.…
Apr 21, 2026
Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
PolicyKFF Health News ↗
Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
Section 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is req…
Apr 21, 2026
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
PolicyFiercePharma ↗
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
Apr 21, 2026